FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, will present at the virtual KeyBanc Annual Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024 at 4:30 p.m. ET. Live and archived webcasts of the presentation will be available through the Omnicell website at: https://ir.omnicell.com/events-and-presentations/ About Omnicell Since 1992, Omnicell has been committed to transforming pharmacy care through outcomes-centri ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNICELL, INC. (Exact name of regis ...

zhihao/Moment via Getty Images Investment thesis Omnicell (NASDAQ:OMCL) has built a highly differentiated portfolio of products and services in the medication dispensing market that puts it, in my opinion, in a strongly advantageous position as the company is building a strong moat that will allow it to stay highly profitable and enjoy high and stable revenue streams in the long term, which should translate into significant (and hopefully steady) returns for investors once a more mature stage is reached. Th ...

Omnicell, Inc. (OMCL) reported fourth-quarter 2023 adjusted earnings per share (EPS) of 33 cents, in line with the year-over-year figure. However, the metric beat the Zacks Consensus Estimate of 17 cents.Adjustments include one-time expenses like share-based compensations, the amortization of acquired intangibles, acquisition-related expenses, executive transition costs, severance-related expenses and others.GAAP loss was 32 cents per share in the quarter under review compared with 64 cents in the prior-yea ...

Omnicell, Inc. (NASDAQ:OMCL) Q4 2023 Earnings Conference Call February 8, 2024 8:30 AM ET Company Participants Kathleen Nemeth - SVP of IR Randall Lipps - Chairman, President, CEO and Founder Nchacha Etta - EVP and CFO Conference Call Participants Stan Berenshteyn - Wells Fargo Anne Samuel - JPMorgan Scott Schoenhaus - KeyBanc Allen Lutz - Bank of America Matt Hewitt - Craig-Hallum Capital Group David Larsen - BTIG Stephanie Davis - Barclays Bill Sutherland - The Benchmark Company Jessica Tassan - Piper San ...

Omnicell (OMCL) is well-poised for growth in the coming quarters, backed by the execution of its vision to transform the pharmacy care delivery model and deliver mission-critical medication management solutions for customers globally. The company is closely managing the cost structure with several initiatives, which are set to benefit its key metrics.Macroeconomic headwinds are resisting the full impact of expense containment efforts.In the past three months, this Zacks Rank #3 (Hold) stock has declined 21. ...

Omnicell, Inc. (NASDAQ:OMCL) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Kathleen Nemeth - SVP of IR Randall Lipps - Chairman, President, CEO and Founder Nchacha Etta - EVP and CFO Conference Call Participants Stan Berenshteyn - Wells Fargo Scott Schoenhaus - KeyBanc Jes Tassan - Piper Sandler David Larsen - BTIG Jack Siedow - Craig-Hallum Bill Sutherland - The Benchmark Company Operator Good morning, my name is Jordan, and I'll be your conference operator today. At thi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 ...

Investor Relations August 1, 2023 This presentation contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP"), including Q2-2023 non-GAAP gross margin, non-GAAP operating expense, nonGAAP EBITDA, and non-GAAP earnings per share, 2017 and Q2-2023 liquidity and 2017 and Q2-2023 net debt/EBITDA, guidance with respect to 2023 non-GAAP EBITDA and non-GAAP earnings per share. Reconciliations of the 2017 and Q2-2023 non-GAAP financial measures to ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNIC ...